Treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis;Therapie der nichtalkoholischen fettleber (NAFL) und fettleberhepatitis (NASH)

Verdauungskrankheiten

Volumn 21, Issue 2, 2003, Pages 94-100

  Leiss O ^a   Linhart, P ^a  

^a DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

Diabetes mellitus and NASH; Drugs affecting steatohepatitis; Obesity; Treatment of NASH

Indexed keywords

AMANTADINE; AMIODARONE; AMITRIPTYLINE; ANTIDIABETIC AGENT; AZACOSTEROL; CHLORCYCLIZINE; CHLOROQUINE; CHLORPHENTERMINE; CHLORPROMAZINE; CHOLINE DERIVATIVE; CLOFIBRATE; COTRIMOXAZOLE; DILTIAZEM; FENFLURAMINE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; IMIPRAMINE; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PERHEXILINE MALEATE; PROPRANOLOL; TAMOXIFEN; TETRAHYDROLIPSTATIN; THIORIDAZINE; TRIPARANOL; TRIPELENNAMINE; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VERAPAMIL;

AGE; CLINICAL TRIAL; HUMAN; HYPERLIPOPROTEINEMIA; LIVER DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE; OBESITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; WEIGHT REDUCTION;

EID: 0038480698     PISSN: 0174738X     EISSN: None     Source Type: Journal    
DOI: 10.5414/vdp21094     Document Type: Review

References (38)

1. Abdelmalek M., P. Angulo, R.A. Jorgensen, P.B. Sylvestre, K.D. Lindor: Betain, a promising new agent for patients with non-alcoholic steatohepatitis: results of a pilot study. Am. J. Gastroenterol. 96, 2711-2717 (2001).
2. Anderson T., C. Gluud, M.B. Franzmann et al.: Hepatic effects of dietary weight loss in morbidly obese patients. J. Hepatol. 12, 224-229 (1991).
3. Angulo P., K.D. Lindor: Treatment of non-alcoholic fatty liver: present and emerging therapies. Seminars in Liver Disease 21, 81-88 (2001).
4. Angulo P: Non-alcoholic fatty liver disease. New Engl. J. Med. 346, 1221-1231 (2002).
5. Basaranoglu M., O. Acbay, A. Sonsuz: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J. Hepatol. 31, 384 (1999).
6. Buchman A.L., M.D. Dubin, A.A. Moukarzel et al.: Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 22, 1390-1403 (1995).
7. Caldwell S.H., E.E. Hespenheide, J.A. Redick, J.C. Iezzoni, E.H. Battle, B.L. Sheppard: A pilot study of a thiazolidinedione, troglitazone, in non-alcoholic steatohepatitis. Am. J. Gastroenterol. 96, 519-525 (2001).
8. Ceriani R., S. Bunati, L. Morini et al.: Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis. Hepatology 28 (Abstract), 386A (1998).
9. Dannenberg A.J., A.A. Nanji: Cyclooxygenase-2: a potential target for the prevention and treatment of alcoholic liver disease. In: Leuschner U., O.F.W. James, H. Dancygier (eds.): Steatohepatitis (NASH and ASH). Kluwer Academic publishers, Dordrecht - Boston - London 2001, 69-74.
10. Davidson M.H., J. Hauptmann, M. DiGirolamo et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281, 235-242 (1999).
11. DeWind L.T., J.H. Payne: Intestinal bypass surgery for morbid obesity. Long term results. JAMA 236, 2298-2301 (1976).
12. Drenick E.J., J. Fisler, D. Johnson: Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 82, 535-548 (1982).
13. Dufour J.-F: Alpha-tocopherol and antioxidants in the treatment of non-alcoholic steatohepatitis. In: Leuschner U., O.F.W. James, H. Dancygier (eds.): Steatohepatitis (NASH and ASH). Kluwer Academic publishers, Dordrecht - Boston - London 2001, 197-202.
14. Eriksson S., K.F. Eriksson, L. Bondesson: Non-alcoholic steatohepatitis in obesity: a reversible condition. Acta Med. Scand. 220, 83-88 (1986).
15. Falck-Ytter Y., Z.M. Younossi, G. Marchesini, A.J. McCullough: Clinical features and natural history of non-alcoholic steatosis syndromes. Seminars in Liver Disease 21, 17-26 (2001).
16. Farrell G.C.: Drugs and non-alcoholic steatohepatitis. In: Leuschner U., O.F.W. James, H. Dancygier (eds.): Steatohepatitis (NASH and ASH). Kluwer Academic Publishers, Dordrecht - Boston - London 2001, 132-139.
17. Franzese A., P. Vajro, A. Argentiano et al.: Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig. Dis. Sci. 42, 1428-1432 (1997).
18. Guma G., L. Viola, M. Thome et al.: Ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: results of a prospective clinical controlled study. Hepatology 26 (Abstract), 387A (1997).
19. Halverson J.D., L. Wise, M.F. Wazna et al.: Jejunoileal bypass for morbid obesity: a critical appraisal. Am. J. Med. 64, 461 (1978).
20. Hollander P., S. Elbien, I. Hirsch et al.: Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomised double-blind study. Diabetes Care 21, 1288-1294 (1998).
21. Husemann B.: Chirurgische Therapie der extremen Adipositas. In: Wechsler J.G. (Hrsg.): Adipositas - Ursachen und Therapie. Blackwell Wissenschafts-Verlag, Berlin - Wien 1998, 267-289.
22. Laurin J., K.D. Lindor, J.S. Crippin et al.: Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23, 1464-1467 (1996).
23. Laurin J.: Clofibrate and other lipid-lowering drugs in the treatment of non-alcoholic steatohepatitis. In: Leuschner U., O.F.W. James, H. Dancygier (eds.): Steatohepatitis (NASH and ASH). Kluwer Academic publishers, Dordrecht - Boston - London 2001, 188-196.
24. Lavine J. E.: Vitamin E treatment of non-alcoholic steatohepatitis in children: a pilot study. J. Pediatr. 136, 734-738 (2000).
25. Marchesini G., M. Brizi, G. Bianchi, S. Tomassetti, M. Zoli, M. Melchionda: Metformin in non-alcoholic steatohepatitis. Lancet 358, 893-894 (2001).
26. Munoz S.: Nutrituional therapies in liver disease. Seminars in Liver Disease 11, 278-291 (1991).
27. Palmer M., F. Schaffner: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99, 1408-1413 (1990).
28. Plevris J.N., P.C. Hayes, I.A.D. Bouchier: Ursodeoxycholic acid in the treatment of alcoholic liver disease. Eur. J. Gastroenterol. Hepatol. 3, 653-656 (1991).
29. Rashid M., E. Roberts: Non-alcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 30, 48-53 (2000).
30. Reid A.: Non-alcoholic steatohepatitis. Gastroenterology 121, 710-723 (2001).
31. Rozental P., C. Biava, H. Spencer et al.: Liver morphology and function tests in obesity and during total starvation. Am. J. Dig. Dis. 12, 198-208 (1967).
32. Saksena S., J. Johnson, P. Milkiewicz, S.P. Olliff, S.G. Hubscher, E. Elias: Diet and exercise: important first steps in the therapy of non-alcoholic fatty liver disease. In: Leuschner U., O.F.W. James, H. Dancygier (eds.): Steatohepatitis (NASH and ASH). Kluwer Academic publishers, Dordrecht Boston - London 2001, 203-212.
33. Schalm S.W., B. von Hoek: Treatment of non-alcoholic steatohepatitis: role of ursodeoxycholic acid. In: Leuschner U., O.F.W. James, H. Dancygier (eds.): Steatohepatitis (NASH and ASH). Kluwer Academic publishers, Dordrecht - Boston - London 2001, 185-187.
34. Sheth S.G., F.D. Gordon, S. Chopra: Non-alcoholic steatohepatitis. Ann. Intern. Med. 126, 137-145 (1997).
35. Ueno T., H. Sugawara, K. Sujaku et al.: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol. 27, 103-107 (1997).
36. Vajro P, A. Fontanella, C. Perna, G. Orso, M. Tedesco, A. De Vincenco: Persistent hyperamino-transferasemia resolving after weight reduction in obese children. J. Pediatr. 125, 239-241 (1994).
37. Vajro P., A. Franzese, G. Valerio, M.P. Iannucci, N. Aragione: Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J. Pediatr. 136, 739-743 (2000).
38. Wensing, J.W.M., R.W. Stockbrügger, R.P. Adang: Ursodeoxycholic acid in alcoholic liver disease. BMJ 11, 588-589 (1998).